DDMAC warns Amgen, Bayer on consumer promotions

Share this article:
DDMAC warns Amgen, Bayer on consumer promotions
DDMAC warns Amgen, Bayer on consumer promotions
The FDA's Division of Drug Marketing, Advertising and Communications issued an untitled letter on a patient brochure for Amgen's Sensipar, which is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.

DDMAC said the 12-page brochure is false or misleading because it omits and minimizes serious risks like that of adynamic bone disease and broadens the indication. The brochure includes a removable PI with full risk information in an interior pocket, but the agency said “this does not mitigate the misleading omission and minimization of risk information in the brochure itself.”

Amgen told Reuters it has ceased dissemination of the brochure, in compliance with DDMAC's request.

The Oct. 27 letter came the same day that the agency issued warning letters to Bayer HealthCare for illegally marketing two OTC aspirin combos. Those letters, concerning Bayer Aspirin With Heart Advantage and Bayer Women's Low Dose Aspirin + Calcium, came two weeks after a pair of powerful congressmen scolded the agency for inaction on the matter. Reps. John Dingell and Bart Stupak (both D-MI) had written FDA to complain that Bayer “ignored FDA recommendations to refrain from marketing such combination products.” The agency said of both: “Notwithstanding your attempt to market this product as a combination drug-dietary supplement, the presence of aspirin in this product…renders the entire product a drug.”

For those keeping score, it's the second time in a month that the agency has warned Bayer on promotions. On Oct. 3, DDMAC slapped the company with a warning letter on TV ads for YAZ.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...